Table of Contents

1 Study Coverage

• 1.1 Glucosylceramidase Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Glucosylceramidase Market Size Growth Rate by Product
  • 1.4.2 AVRRD-02
  • 1.4.3 LTI-291
  • 1.4.4 NCGC-607
  • 1.4.5 Pcgin
  • 1.4.6 Others
• 1.5 Market by End User
  • 1.5.1 Global Glucosylceramidase Market Size Growth Rate by End User
  • 1.5.2 Genetic Disorders
  • 1.5.3 Gaucher Disease
  • 1.5.4 Parkinson's Disease
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Glucosylceramidase Market Size
  • 2.1.1 Global Glucosylceramidase Revenue 2014-2025
  • 2.1.2 Global Glucosylceramidase Sales 2014-2025
• 2.2 Glucosylceramidase Growth Rate by Regions
  • 2.2.1 Global Glucosylceramidase Sales by Regions
  • 2.2.2 Global Glucosylceramidase Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Glucosylceramidase Sales by Manufacturers
  • 3.1.1 Glucosylceramidase Sales by Manufacturers
  • 3.1.2 Glucosylceramidase Sales Market Share by Manufacturers
  • 3.1.3 Global Glucosylceramidase Market Concentration Ratio (CR5 and HHI)
• 3.2 Glucosylceramidase Revenue by Manufacturers
  • 3.2.1 Glucosylceramidase Revenue by Manufacturers (2014-2019)
  • 3.2.2 Glucosylceramidase Revenue Share by Manufacturers (2014-2019)
• 3.3 Glucosylceramidase Price by Manufacturers
• 3.4 Glucosylceramidase Manufacturing Base Distribution, Product Types
  • 3.4.1 Glucosylceramidase Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Glucosylceramidase Product Type
  • 3.4.3 Date of International Manufacturers Enter into Glucosylceramidase Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Glucosylceramidase Sales by Product
• 4.2 Global Glucosylceramidase Revenue by Product
• 4.3 Glucosylceramidase Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Glucosylceramidase Breakdown Data by End User

6 North America

• 6.1 North America Glucosylceramidase by Countries
  • 6.1.1 North America Glucosylceramidase Sales by Countries
  • 6.1.2 North America Glucosylceramidase Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Glucosylceramidase by Product
• 6.3 North America Glucosylceramidase by End User

7 Europe

• 7.1 Europe Glucosylceramidase by Countries
  • 7.1.1 Europe Glucosylceramidase Sales by Countries
  • 7.1.2 Europe Glucosylceramidase Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Glucosylceramidase by Product
• 7.3 Europe Glucosylceramidase by End User

8 Asia Pacific

• 8.1 Asia Pacific Glucosylceramidase by Countries
  • 8.1.1 Asia Pacific Glucosylceramidase Sales by Countries
  • 8.1.2 Asia Pacific Glucosylceramidase Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Glucosylceramidase by Product
• 8.3 Asia Pacific Glucosylceramidase by End User

9 Central & South America

• 9.1 Central & South America Glucosylceramidase by Countries
  • 9.1.1 Central & South America Glucosylceramidase Sales by Countries
  • 9.1.2 Central & South America Glucosylceramidase Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Glucosylceramidase by Product
• 9.3 Central & South America Glucosylceramidase by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Glucosylceramidase by Countries
  • 10.1.1 Middle East and Africa Glucosylceramidase Sales by Countries
  • 10.1.2 Middle East and Africa Glucosylceramidase Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Glucosylceramidase by Product
• 10.3 Middle East and Africa Glucosylceramidase by End User

11 Company Profiles

• 11.1 Amicus Therapeutics, Inc.
  • 11.1.1 Amicus Therapeutics, Inc. Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Amicus Therapeutics, Inc. Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Amicus Therapeutics, Inc. Glucosylceramidase Products Offered
  • 11.1.5 Amicus Therapeutics, Inc. Recent Development
• 11.2 Bioorganic Research and Services S.A.
  • 11.2.1 Bioorganic Research and Services S.A. Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bioorganic Research and Services S.A. Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bioorganic Research and Services S.A. Glucosylceramidase Products Offered
  • 11.2.5 Bioorganic Research and Services S.A. Recent Development
• 11.3 greenovation Biotech GmbH
  • 11.3.1 greenovation Biotech GmbH Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 greenovation Biotech GmbH Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 greenovation Biotech GmbH Glucosylceramidase Products Offered
  • 11.3.5 greenovation Biotech GmbH Recent Development
• 11.4 JCR Pharmaceuticals Co., Ltd.
  • 11.4.1 JCR Pharmaceuticals Co., Ltd. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 JCR Pharmaceuticals Co., Ltd. Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 JCR Pharmaceuticals Co., Ltd. Glucosylceramidase Products Offered
  • 11.4.5 JCR Pharmaceuticals Co., Ltd. Recent Development
• 11.5 Pharming Group N.V.
  • 11.5.1 Pharming Group N.V. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Pharming Group N.V. Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Pharming Group N.V. Glucosylceramidase Products Offered
  • 11.5.5 Pharming Group N.V. Recent Development
• 11.6 Protalix BioTherapeutics, Inc.
  • 11.6.1 Protalix BioTherapeutics, Inc. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Protalix BioTherapeutics, Inc. Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Protalix BioTherapeutics, Inc. Glucosylceramidase Products Offered
  • 11.6.5 Protalix BioTherapeutics, Inc. Recent Development
• 11.7 Shire Plc
  • 11.7.1 Shire Plc Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Shire Plc Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Shire Plc Glucosylceramidase Products Offered
  • 11.7.5 Shire Plc Recent Development
• 11.8 The International Biotechnology Center (IBC) Generium
  • 11.8.1 The International Biotechnology Center (IBC) Generium Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 The International Biotechnology Center (IBC) Generium Glucosylceramidase Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 The International Biotechnology Center (IBC) Generium Glucosylceramidase Products Offered
  • 11.8.5 The International Biotechnology Center (IBC) Generium Recent Development

12 Future Forecast

• 12.1 Glucosylceramidase Market Forecast by Regions
  • 12.1.1 Global Glucosylceramidase Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Glucosylceramidase Revenue Forecast by Regions 2019-2025
• 12.2 Glucosylceramidase Market Forecast by Product
  • 12.2.1 Global Glucosylceramidase Sales Forecast by Product 2019-2025
  • 12.2.2 Global Glucosylceramidase Revenue Forecast by Product 2019-2025
• 12.3 Glucosylceramidase Market Forecast by End User
• 12.4 North America Glucosylceramidase Forecast
• 12.5 Europe Glucosylceramidase Forecast
• 12.6 Asia Pacific Glucosylceramidase Forecast
• 12.7 Central & South America Glucosylceramidase Forecast
• 12.8 Middle East and Africa Glucosylceramidase Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Glucosylceramidase Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Glucosylceramidase market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Glucosylceramidase market based on company, product type, end user and key regions.

This report studies the global market size of Glucosylceramidase in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Glucosylceramidase in these regions.
This research report categorizes the global Glucosylceramidase market by top players/brands, region, type and end user. This report also studies the global Glucosylceramidase market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amicus Therapeutics, Inc.
Bioorganic Research and Services S.A.
greenovation Biotech GmbH
JCR Pharmaceuticals Co., Ltd.
Pharming Group N.V.
Protalix BioTherapeutics, Inc.
Shire Plc
The International Biotechnology Center (IBC) Generium

Market size by Product
AVRRD-02
LTI-291
NCGC-607
Pcgin
Others
Market size by End User
Genetic Disorders
Gaucher Disease
Parkinson's Disease
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Glucosylceramidase market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Glucosylceramidase market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Glucosylceramidase companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Glucosylceramidase submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Glucosylceramidase are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Glucosylceramidase market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.